OncoMatch/Clinical Trials/NCT05069220

18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor

Is NCT05069220 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies multiple treatments including 18F-MFBG and 68Ga-Dotatate for neuroendocrine tumor.

Early Phase 1RecruitingPeking Union Medical College HospitalNCT05069220Data as of May 2026

Treatment: 18F-MFBG · 68Ga-Dotatate — The aim of this study is to evaluate the diagnostic performance and tumor burden of 18F-metafluorobenzylguanidine (18F-MFBG) positron emission tomography (PET) in patients with neuroendocrine tumors mainly in pheochromocytoma and paraganglioma (PPGL) and neuroblastoma (NB).

Check if I qualify

Extracted eligibility criteria

Cancer type

Neuroendocrine Tumor

Neuroblastoma

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify